Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
OTONOMY, INC. (OTIC) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/28/2023 8-K Quarterly results
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/29/2022 8-K Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balan...
Docs: "Lease Termination Agreement"
12/19/2022 8-K Quarterly results
11/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/24/2022 8-K Quarterly results
10/14/2022 8-K Results of Operations and Financial Condition  Interactive Data
09/16/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/09/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
08/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus • OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints • Company to discontinue development of OTO-313 and implement other measures to extend its cash runway • Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022 SAN DIEGO, August 1, 2022"
07/25/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss"
02/28/2022 8-K Quarterly results
01/06/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Otonomy Reports Corporate and Product Pipeline Update Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, January 6, 2022 -- Otonomy, Inc. , a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. Consistent with previously stated timing, the company expects to report results for the Phase 2a cohort of OTO-413 in hearing loss patients early in the second quarter of 2022 and the Phase 2 trial of OTO-313 in tinnitus patients in mid-2022. The company also plans to initiate a clinical safety evaluation of higher unilateral as well as bilateral dosing of OTO..."
11/10/2021 8-K Quarterly results
Docs: "Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update  OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022  Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022  Initiating clinical safety evaluation of higher dosing for OTO-413 to support full dose-ranging Phase 2 efficacy trial expected to start by the end of 2022  OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, November 10, 2021"
08/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Otonomy Appoints Jill Broadfoot to Board of Directors"
08/04/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, between Otonomy, Inc. and Cowen and Company, LLC",
"Sales Agreement, between Otonomy, Inc. and Cowen and Company, LLC"
08/04/2021 8-K Quarterly results
Docs: "Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
06/24/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/08/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Enrollment completed in Phase 3 clinical trial of OTIVIDEX ® in Ménière’s disease with results expected in the first quarter of 2021 • Positive results reported for Phase 1/2 clinical trial of OTO-313 in tinnitus patients • Enrollment completed in Phase 1/2 clinical trial of OTO-413 in hearing loss with results expected by end of year • Public offering completed for total gross proceeds of $69.1 million Conference call and webcast today at 4:30 p.m. ET"
08/04/2020 8-K Quarterly results
07/10/2020 8-K Quarterly results
07/09/2020 8-K Quarterly results
07/06/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
04/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Otonomy Provides Business Update Related to COVID-19 Pandemic"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy